Keywords: Merck KGaA, Erbitux, Gastric adenocarcinoma, Diagnostic collaboation Sanofi, Job cuts, Yves Rocher divestment

News briefs from Merck KGaA and Sanofi

Article | 05 July 2012

Print This

German drug major Merck KGaA )MRK: DE) revealed this morning that its Phase III EXPAND trial, which assessed Erbitux (cetuximab) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in